10x Genomics Inc (TXG) shares decline 4.65% on July 21 amid reduced trading volume.

10x Genomics Inc's (TXG) shares fell 4.65% on Jul 21, reaching an intraday low of $11.45. Trading volume was 1,227,225 shares, 31.9% of the average daily volume of 3,842,016. Based on 13 analysts' one-year price targets, the average target price is $13.54, indicating a potential upside of 16.86% from the current price.

On July 21, 10x Genomics Inc's (TXG) shares fell by 4.65%, reaching an intraday low of $11.45. The trading volume was 1,227,225 shares, which represented 31.9% of the average daily volume of 3,842,016 shares. Based on the one-year price targets from 13 analysts, the average target price stands at $13.54, indicating a potential upside of 16.86% from the current price [2].

The decline in share price comes amidst a consensus rating of "Hold" from analysts, with a mix of "Sell," "Hold," and "Buy" ratings [2]. The average one-year price target suggests that investors are cautious about the stock's immediate prospects but see potential for growth over the longer term.

Adding to the company's recent developments, 10x Genomics has partnered with the A*STAR Genome Institute of Singapore to launch the TISHUMAP study. This collaboration aims to analyze up to 2,500 formalin-fixed paraffin-embedded (FFPE) clinical tissue samples from gastric, liver, and colorectal cancers using the company's advanced Xenium platform. The study seeks to enhance drug target discovery using spatial biology and AI, potentially leading to new diagnostics and personalized treatments for cancer and inflammatory diseases [1].

The partnership signifies a significant advancement in the application of spatial biology and AI, particularly for cancers prevalent in Asia, which exhibit distinct molecular features compared to Western populations. Dr. Shyam Prabhakar, Associate Director of A*STAR GIS, highlighted the transformative potential of this collaboration, emphasizing its role in precision medicine and improved patient outcomes.

Despite the recent drop in share price, the company's partnership with A*STAR Genome Institute of Singapore underscores its commitment to innovation and scientific advancement. This collaboration could pave the way for future breakthroughs in personalized medicine and cancer treatment.

References:
[1] https://www.gurufocus.com/news/2984507/10x-genomics-and-astar-genome-institute-of-singapore-launch-tishumap-study-to-advance-aidriven-drug-target-discovery-txg-stock-news
[2] https://www.marketbeat.com/instant-alerts/10x-genomics-nasdaqtxg-receives-consensus-rating-of-hold-from-analysts-2025-07-19/